This article was originally published in The Tan Sheet
Brands targeted as acquisition candidates likely would be $10 mil.-$50 mil. businesses in the OTC category that are advertising sensitive, Chattem notes during Deutsche Bank Securities Small Cap Growth Conference Feb. 16. The firm states it would stay out of "huge categories with a lot of bigger players." Acquisitions, however, are not a priority for Chattem, as it currently is more interested in licensing new technology for use in skin care and pain relief than buying standalone brands (1"The Tan Sheet" Feb. 6, 2006, p. 6)...
You may also be interested in...
Chattem is focused on acquiring technology rather than new brands, the firm said during a report on fourth-quarter and fiscal year 2005 (ended Nov. 30)
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.